share_log

Citigroup Downgrades Cano Health to Neutral, Lowers Price Target to $0.8

Citigroup Downgrades Cano Health to Neutral, Lowers Price Target to $0.8

花旗集团将Cano Health的评级下调至中性,将目标股价下调至0.8美元
Benzinga ·  2023/08/11 05:36

Citigroup analyst Jason Cassorla downgrades Cano Health (NYSE:CANO) from Buy to Neutral and lowers the price target from $4 to $0.8.

花旗集团分析师杰森·卡索拉将Cano Health(纽约证券交易所代码:CANO)的评级从买入下调至中性,并将目标股价从4美元下调至0.8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发